Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. New therapies (like Leqvio) and off-label uses of GLP-1s should always be discussed with your cardiologist or primary care provider.
In This Deep Dive:
- The Hierarchy: Statins vs. PCSK9 Inhibitors (Repatha/Praluent) vs. siRNA (Leqvio)
- The Genetic Lottery: How the PCSK9 gene controls your destiny
- The Paradigm Shift: Is Inflammation the real killer?
- Why GLP-1s (Ozempic/Zepbound) are becoming heart drugs
For decades, the "Lipid Hypothesis" has been the operating system of cardiology: Lower the LDL cholesterol, lower the heart attack risk. It is the reason statins are one of the most prescribed drugs in history.
But for many in the maker and bio-hacking community, the standard algorithm isn't enough. Some are genetically resistant to statins; others suffer side effects. More importantly, new science suggests we might be focusing too much on the "fuel" (cholesterol) and ignoring the "spark" (inflammation). In this guide, we break down the cutting-edge toolset for vascular health, from genetic silencers to inflammation crushers.
The Toolkit: From Pills to Genetic Hacking
If diet and exercise aren't moving the needle, modern medicine offers three distinct tiers of intervention. Think of them as software patches for your liver.
Statins & Ezetimibe
Lipitor, Crestor, Zetia
Mechanism: Statins stop the liver from creating cholesterol (inhibiting HMG-CoA reductase). Ezetimibe stops you from absorbing it from food.
Pros: Dirt cheap, decades of data.
Cons: Muscle pain, blood sugar spikes, daily pill fatigue.
PCSK9 Inhibitors
Repatha (Evolocumab), Praluent (Alirocumab)
Mechanism: These are monoclonal antibodies (man-made proteins) that hunt down and neutralize the PCSK9 protein in your blood, forcing your liver to clear more LDL.
The Experience: A self-injection every 2–4 weeks.
siRNA Therapy
Leqvio (Inclisiran)
Mechanism: Instead of hunting the protein, Leqvio enters the liver cells and degrades the mRNA that codes for the protein. It stops the factory line.
The Experience: Just two shots a year (after initial loading).
The Genetic Component (PCSK9)
Why do some people eat keto/carnivore diets and have perfect lipids, while others eat salads and have LDL over 200? The answer often lies in the PCSK9 gene.
The PCSK9 protein is essentially a "recycling manager" gone wrong. It tells your liver to destroy its own LDL receptors.
- Gain-of-Function Mutation (Bad): Your body makes too much PCSK9. Your liver destroys its receptors, and LDL builds up in your blood. This is known as Familial Hypercholesterolemia (FH).
- Loss-of-Function Mutation (Good): Some lucky individuals are born with broken PCSK9. They have naturally ultra-low cholesterol and almost zero heart disease risk. Drugs like Repatha and Leqvio are simply trying to mimic this genetic mutation.
The Pivot: Fuel vs. Fire
This is the most controversial and exciting topic in cardiology right now. Is high cholesterol actually the problem?
The "Response to Injury" Model
Think of LDL cholesterol as dry wood (fuel). Think of inflammation as the spark. You can stack wood in your living room safely for years. But if you introduce a spark (inflammation from smoking, high sugar, stress, or leaky gut), the house burns down.
Recent studies (such as the CANTOS trial) have shown that reducing inflammation can lower cardiovascular events independent of cholesterol levels. This is why physicians are now obsessed with a lab marker called hs-CRP (High-Sensitivity C-Reactive Protein). If your LDL is low but your CRP is high, you are still at risk.
Why Ozempic & Zepbound are Heart Drugs
You know them as weight loss drugs, but the FDA recently approved Wegovy (semaglutide) specifically for reducing cardiovascular risk. Why?
It isn't just because patients lose weight. GLP-1 agonists (like Ozempic, Wegovy, Zepbound) appear to have a direct anti-inflammatory effect on the endothelial lining of blood vessels.
- Plaque Stability: They may make existing plaque less likely to rupture.
- Systemic Cooling: By lowering systemic inflammation, they remove the "spark" mentioned above.
The Future Stack: We are moving toward a future where a patient might take Leqvio (twice a year) to remove the fuel, and a low-dose GLP-1 to remove the inflammation—offering total vascular protection.
Optimize Your Health Stack
Join "Great Meets" to discuss bio-data, lab results, and the latest health tech with our community.
Sign Up Free